Well Referenced

Tag: advanced cancer

Safety of intravenously applied mistletoe extract – results from a phase I dose escalation study in patients with advanced cancer

This phase I dose-escalation trial investigated the safety and tolerability of intravenous mistletoe extract (Helixor® P) in 21 patients with advanced, treatment-resistant malignancies. Doses ranged from 200 to 2000 mg weekly over a 3-week period, with a 9-week extension for high-dose patients. The maximum tolerated dose was not reached. One

Read More »
June 26, 2025 No Comments

Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced Cancer. A Controlled Trial (1979)

This randomized, double-blind, placebo-controlled trial evaluated the efficacy of high-dose oral vitamin C (10 g/day) in 150 patients with advanced cancer. The study found no significant differences between the vitamin C and placebo groups in terms of symptom improvement, performance status, appetite, weight, or survival duration. The median survival for

Read More »
June 26, 2025 No Comments

Trial of Mistletoe Extract in Patients With Advanced Solid Tumors

This Phase I clinical trial (NCT03051477) evaluates the safety, toxicity, and maximum tolerated dose (MTD) of Helixor® M (mistletoe extract) in 21 patients with advanced solid tumors who have not responded well to first-line therapies. The study consists of a dose escalation phase to assess safety and an expansion phase

Read More »
June 26, 2025 No Comments

Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer

This observational cohort study evaluated the clinical safety of combining immune checkpoint inhibitors (ICIs) with Viscum album L. (mistletoe) extract in patients with advanced or metastatic cancer. Sixteen patients were included, with nine receiving both ICI and mistletoe therapy. The study found no statistically significant increase in adverse events (67%

Read More »
June 26, 2025 No Comments